Differential effects of EGF and amphiregulin on adhesion molecule expression and migration of colon carcinoma cells.
Epidermal growth factor (EGF) is a potent morphogen affecting cell shape and motility through regulation of adhesive interactions. We have characterized the morphological effects of EGF on GP2d and GP5d colon carcinoma cell lines and have compared the ability of the heparin-binding EGF receptor ligand amphiregulin (AR) to elicit the same effects. EGF induced a marked epithelial-mesenchymal transition in both cell lines. This effect was evident at 7 pM EGF and was associated with a reduction in cellular adherens junctions and diminished cell-cell contact; it was also associated with an increase in expression of alpha2-integrin as well as enhanced adhesion to the substratum and cell spreading. These changes in adhesion molecule expression were accompanied by enhanced migration on collagen. Blockade of cell growth with mitomycin C did not prevent the EGF-induced morphological change, showing that the mitogenic and morphogenic responses of the GP cells were separable. The phosphatidyl inositol (PI) 3-kinase inhibitor wortmannin inhibited basal proliferation but had no effect on the EGF-induced morphological change, further suggesting that the PI 3-kinase pathway was not involved in the morphogenic response of these cells. Amphiregulin stimulated proliferation of both cell lines, but could only elicit a modest morphological change if used at considerably higher doses or if growth was blocked with mitomycin C. In cells treated with 55 nM AR, alpha2-integrin expression was slightly increased; however, unlike the EGF case, adherens junctions remained intact. These differences in the ability of EGF and amphiregulin to affect cellular adhesion and migration may be significant factors influencing normal and tumor cell behavior.
Solic
N
N
CRC Wessex Medical Oncology Unit, CF99 Southampton General Hospital, United Kingdom.
Davies
D E
DE
D000230:Adenocarcinoma / Q000737:chemistry / Q000473:pathology*; D066258:Amphiregulin; D000730:Androstadienes / Q000494:pharmacology; D015703:Antigens, CD / Q000032:analysis; D015820:Cadherins / Q000032:analysis; D002448:Cell Adhesion; D015815:Cell Adhesion Molecules / Q000032:analysis*; D002455:Cell Division / Q000187:drug effects; D002465:Cell Movement / Q000187:drug effects*; D003110:Colonic Neoplasms / Q000737:chemistry / Q000473:pathology*; D004791:Enzyme Inhibitors / Q000494:pharmacology; D004815:Epidermal Growth Factor / Q000494:pharmacology*; D004848:Epithelium; D066246:ErbB Receptors / Q000378:metabolism; D006023:Glycoproteins / Q000494:pharmacology*; D006133:Growth Substances / Q000494:pharmacology*; D039421:Integrin alpha2; D007365:Intercellular Junctions; D036341:Intercellular Signaling Peptides and Proteins; D008024:Ligands; D008648:Mesoderm; D016685:Mitomycin / Q000494:pharmacology; D019384:Nucleic Acid Synthesis Inhibitors / Q000494:pharmacology; D019869:Phosphatidylinositol 3-Kinases; D017853:Phosphotransferases (Alcohol Group Acceptor) / Q000037:antagonists & inhibitors / Q000502:physiology; D000077191:Wortmannin
D066258:Amphiregulin; D000730:Androstadienes; D015703:Antigens, CD; D015820:Cadherins; D015815:Cell Adhesion Molecules; D004791:Enzyme Inhibitors; D006023:Glycoproteins; D006133:Growth Substances; D039421:Integrin alpha2; D036341:Intercellular Signaling Peptides and Proteins; D008024:Ligands; D019384:Nucleic Acid Synthesis Inhibitors; D016685:Mitomycin; D004815:Epidermal Growth Factor; D019869:Phosphatidylinositol 3-Kinases; D017853:Phosphotransferases (Alcohol Group Acceptor); D066246:ErbB Receptors; D000077191:Wortmannin